The US Food and Drug Administration has approved Darzalex Faspro (daratumumab and hyaluronidase-FiHZ) in combination with bortezomib, lenalidomide, and dexamethasone (D-VRD) for the treatment of adult patients with newly diagnosed multiple myeloma (MM) ineligible for autologous stem cell transplant (ASCT).
Please follow and like us:
